European patient organisations EUROPEAN MYELOMA PLATFORM and MYELOMA EURONET have today officially announced at the European Hematology Association Meeting in London that they have taken the decision to merge. Joining forces will provide a stronger network and offer huge benefits to myeloma patients and their families across Europe. Download the entire press release
BRUSSELS, Belgium, October 3, 2007 – Thalidomide was introduced as a sedative in Europe and Canada in the late 1950s, and was widely used to treat insomnia and nausea during pregnancy.
BRUSSELS, Belgium BRUSSELS, Belgium, June 29 -- The European Myeloma Platform (EMP) says updated data for previously treated patients on REVLIMID (lenalidomide) plus the steroid dexamethasone show median survival of 35 months, nearly three years.
Brussels, Belgium – (June 20, 2007) – The European Myeloma Platform (EMP) applauds the EMEA decision to grant marketing authorization for REVLIMID (lenalidomide) for the treatment of patients with multiple myeloma who have received at least one prior therapy.
New Clinical Data Reports 100% Response Rate for Elderly Patients, After Two-Years of Follow-up